Phaseline

Companies › Insmed

Insmed: clinical trials, targets and expected readouts

2 active drug programs in 11 registered trials: 5 Phase 3, 3 Phase 2, 3 Phase 1; Other, Cardiovascular, Gastroenterology, Respiratory; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Treprostinil
Prostanoid IP receptor agonist
PTGIRPhase 3Pulmonary Arterial Hypertension; Pulmonary Hypertension; Progressive Pulmonary Fibrosis; Hepatic Impairment …Dec 2026
INS1033–Phase 1Healthy VolunteersMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04062565TreprostinilPhase 3Pulmonary Arterial HypertensionCardiovascularDec 2025
NCT05649748TreprostinilPhase 2Pulmonary Arterial HypertensionCardiovascularDec 2026
NCT06969573TreprostinilPhase 2COPD (Chronic Obstructive Pulmonary Disease)RespiratoryDec 2026
NCT07643155TreprostinilPhase 1Hepatic ImpairmentGastroenterologyFeb 2027
NCT07765706INS1033Phase 1Healthy VolunteersOtherMar 2027
NCT07037836TreprostinilPhase 2COPD (Chronic Obstructive Pulmonary Disease)RespiratoryJul 2027
NCT04005469TreprostinilPhase 1Ischemia Reperfusion InjuryOtherJun 2028
NCT07481981TreprostinilPhase 3Pulmonary Arterial HypertensionCardiovascularDec 2028
NCT07179380TreprostinilPhase 3Pulmonary HypertensionCardiovascularDec 2028
NCT07805785TreprostinilPhase 3Progressive Pulmonary FibrosisRespiratoryAug 2030
NCT07234032TreprostinilPhase 3Pulmonary HypertensionCardiovascularJan 2031

From the company's SEC filings

Cash and short-term investments of $1.1bn on 2026-09-30; operating cash outflow about $467m a year; runway about 30 months at that burn, to Mar 2029; 5 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Targets

PTGIR (1)

Companies with the same targets

Johnson & Johnson (Janssen) Liquidia Technologies United Therapeutics

Companies built like this

Liquidia Technologies Eloxx Pharmaceuticals Tenax Therapeutics Kymera Therapeutics Shanghai Synvida Biotechnology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.